Polyneuropathy

NeurogesX Announces Resignation of Bruce A. Peacock from Board of Directors

... management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch desig...

NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM)

... management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch desig...

GBS/CIDP Foundation International Appoints Patricia A. Bryant as Executive Director

...ional, the only non-profit organization dedicated to serving patients afflicted with Guillain-Barre Syndrome (GBS), Chronic Inflammatory Demyelinating polyneuropathy (CIDP) and variants, announced the appointment of Patricia A. Bryant to the position of Executive Director effective as of May 2009. Patricia succeed...

New Jefferson study may redefine how a chronic auto-immune disease is diagnosed

... PHILADELPHIA New research from Jefferson Hospital for Neuroscience (JHN) may redefine how Chronic Inflammatory Demyelinating polyneuropathy (CIDP) is diagnosed. Eduardo De Sousa, M.D., assistant professor of Neurology at Jefferson Medical College of Thomas Jefferson University, and direct...

NORD to Honor Rare Disease Pioneers

... Talecris Biotherapeutics, Inc., for developing Gamunex(R), the first therapy approved for treating people with chronic inflammatory demyelinating polyneuropathy ViroPharma, Inc., for making available to patients Cinryze(R), the first drug approved by FDA to prevent swelling that occurs in various body ...

Landmark study demonstrates Gamunex improves health-related quality of life in patients with CIDP

...ation of the health-related quality of life results from the largest clinical trial ever conducted in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) in the April 14, 2009 issue of Neurology . The data demonstrate that long-term treatment with Gamunex (Immune Globulin Intravenous (Human), 1...

CIDP Treated With Plasma-Derived Therapy

... Patients with rare, chronic inflammatory demyelinating polyneuropathy (CIDP) depend on plasma donation ANNAPOLIS, Md. , April 24 /PRNewswire/ -- Chronic inflammatory demyelinating polyneuropathy (CIDP) is a debilitating, progressive neurological disorder that results in...

Type of vitamin B1 could treat common cause of blindness

...clinical trials have shown that benfotiamene is absorbed better than thiamine [the most common form of vitamin B1] and significantly improved diabetic polyneuropathy in patients, and it's already taken as a supplement for diabetic complications," Ramana said. ...

NeurogesX Reports Fourth Quarter and Year-End 2008 Results

... management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late-stage product portfolio is led by its product candidate Qutenza(TM), a dermal high-co...

LSUHSC's England leads development of new testing guidelines for common nerve disorder

... nerves can be involved producing different symptoms and levels of damage. According to the National Institutes of Health, in the most common forms of polyneuropathy (multiple nerve involvement), the nerve fibers (individual cells that make up the nerve) most distant from the brain and the spinal cord malfunction f...

Polyneuropathy in Medical Technology

NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy

SAN CARLOS, Calif., Sept. 21 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX ) announced today that it has completed enrollment in study C119, a second Phase 3 clinical trial of its lead product candidate NGX-4010 for the treatment of painful HIV-distal sensory polyneuropathy (HIV-DSP...

NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy

SAN CARLOS, Calif., Sept. 21 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX ) announced today that it has completed enrollment in study C119, a second Phase 3 clinical trial of its lead product candidate NGX-4010 for the treatment of painful HIV-distal sensory polyneuropathy (HIV-DSP...

NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study

... management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch desig...

NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia

... management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch desig...

NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology

... management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late-stage product portfolio is led by its product candidate Qutenza, a dermal patch desig...

NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation

... management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch desi...

NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology

...led study involving 307 patients with painful HIV-associated distal sensory polyneuropathy (HIV-DSP) receiving a single application of NGX-4010, a high-concentration ...ic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage prod...

NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP

...results from study C119, its second Phase 3 clinical trial of NGX-4010, the Company's dermal patch drug candidate, in patients with HIV-distal sensory polyneuropathy (HIV-DSP). The prespecified analysis of the primary endpoint, comparing all patients treated with NGX-4010 compared to all patients treated with the c...

Immunosyn Releases Wound Healing Photographs From the First Phase 'Proof of Concept Trial' in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019

... SF-1019 in the treatment of Diabetic Ulceration and its effect on Diabetic polyneuropathy in Type 1 Diabetes Mellitus by both subcutaneous injection and by topical a... (MS) and neurological disorders such as Chronic Inflammatory Demyelinating polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS). (For more i...

Immunosyn Announces Biozyme Lab's Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019

... and diabetic ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS) and neurological disorders such as Chronic Inflammatory Demyelinating polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS). (For more information on Immunosyn and SF-1019 go to http://www.immunosyn.com ). Th...

Polyneuropathy in Medical Dictionary

Polyneuropathy

Polyneuropathy is a neurological disorder that occurs when many peripheral nerves throughout the body malfunction simultaneously. It may be acute and appear without warning, or chronic and develop gradually over a longer period of time. Many polyneuropathies have both... List of 5 dise...

Mononeuropathy

...avannah Georgia GA, South Carolina SC St. Joseph_ s/Candler, Savannah Georgia GA, South Carolina SC OVERVIEW The high incidence of a systemic polyneuropathy in end-stage renal disease predisposes to the development of clinically apparent mononeuropathies 1 1 . The ... ...

Guillain

... Guillain -Barré syndrome (GBS), also known as Landry- Guillain -Barré-Strohl syndrome, is an acute inflammatory demyelinating polyneuropathy (AIDP), an autoimmune disorder affecting the peripheral nervous system, usually triggered by an acute infectious process. It is... Guillain ...

Polyneuropathy in Biological Technology

NeurogesX Reports Second Quarter 2009 Results

... management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza(TM), a dermal patch d...

NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application

... management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza(TM), a dermal patch d...

NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results

... management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza((TM)), a dermal patch...

NeurogesX Added to Russell 3000 Index

... management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch desig...

NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)

... management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch desig...

NeurogesX to Present at Needham Life Sciences Conference

... management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza(TM), a dermal patch d...

NeurogesX Receives European Commission Approval for Qutenza(TM)

...es, in cases of postherpetic neuralgia (PHN) and painful HIV-distal sensory polyneuropathy (HIV-DSP), or diseases, such as diabetes. An estimated 8% of the world...ic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage prod...

NeurogesX Reports First Quarter 2009 Results

... management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late-stage product portfolio is led by its product candidate QutenzaTM, a dermal high-conc...

NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results

... management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch desig...

NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting

...end aberrant pain signals to the brain, in the absence of harmful stimuli. It can result from viruses, in cases of PHN and painful HIV-distal sensory polyneuropathy (HIV-DSP), or diseases, such as diabetes. An estimated 8% of the world's population suffers from neuropathic pain. Treatments to address the est...